What one share of Artelo Biosciences holds
We incorporated in the State of Nevada on May 2, 2011, and are presently based in the County of San Diego, California. We are a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system (the “ECS”), a network of receptors and neurotransmitters that form a biochemical communication system throughout the body.
Artelo Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$11.45 |
|---|---|
| Cash and investments | $6.24 |
| Book value | $7.42 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$54.89 | — | — | — | $15.10 |
| 2025 | — | −$37.55 | — | — | — | −$1.89 |
Common questions about Artelo Biosciences
How much does one share of Artelo Biosciences earn?
Over the last 12 months, Artelo Biosciences lost $11.45 for each share.
Does Artelo Biosciences pay a dividend?
Artelo Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Artelo Biosciences’s book value per share?
Artelo Biosciences’s book value is $7.42 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Artelo Biosciences have?
Each share of Artelo Biosciences has $6.24 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.